Navigation Links
Spartan Bioscience Names Charudutt Shah as Director of Business Development
Date:8/26/2014

Ottawa, Ontario (PRWEB) August 26, 2014

Spartan Bioscience today announced the appointment of Charudutt Shah as its Director of Business Development. Mr. Shah is responsible for expanding distribution of the Spartan RX CYP2C19 System in the United States and international markets. He is also responsible for new business opportunities and strategic initiatives for the company’s rapid sample-to-result genotyping platform.

Prior to joining Spartan, Mr. Shah was the Global Marketing Product Manager for Infectious Disease products at Luminex. He established Luminex’s international sales and distribution channels for molecular diagnostic products. Also, he was responsible for executing commercial strategies to achieve global sales targets. Prior to Luminex, Mr. Shah worked at Life Technologies and Toxikon Corporation.

“We are delighted that Charudutt Shah has joined our management team at Spartan Bioscience,” said Paul Lem, M.D., CEO of Spartan Bioscience. “Charudutt has deep experience in the molecular diagnostic industry and he will have an immediate impact on our business development efforts.”

About the Spartan RX CYP2C19 System
The Spartan RX CYP2C19 System is the first rapid pharmacogenetic test in medicine.(1) It identifies carriers of certain CYP2C19 genetic mutations in 1 hour. The CYP2C19 enzyme metabolizes approximately 15 percent of all prescribed drugs(2), including important drug classes such as antiplatelet therapies, beta blockers, antidepressants, proton pump inhibitors, and anti-epileptics. About 30% of Caucasians, and more than 50% of Asians and Indians carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(3,4,5,6)

The Spartan RX CYP2C19 System has FDA 510(k) regulatory clearance for the United States, and CE IVD Mark regulatory approval for Europe and other countries recognizing the CE IVD Mark. For more information, please visit our website at: http://www.spartanbio.com/products/spartan-rx/overview/.

About Spartan Bioscience
Spartan Bioscience is the leader in on-demand DNA testing. Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.

The Spartan logo is a registered trademark of Spartan Bioscience Inc.

1. Roberts JD et al. (2012). Lancet. 379:1705–11.
2. dbSNP Short Genetic Variations. Reference SNP (refSNP) Cluster Report: rs12248560
3. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.
4. Chen M et al. (2011). Atherosclerosis. 220(1):168–71.
5. Oh IY et al. (2012). Heart. 98(2):139–44.
6. Jose R et al. (2004). Fundamental & Clinical Pharmacology. 19(1): 101–105.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12113718.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents
2. First Point-of-Care DNA Test Submitted for FDA Clearance by Spartan Bioscience
3. Spartan Bioscience Receives FDA Clearance for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs
4. Spartan Bioscience Announces Medical Device Registration of Rapid CYP2C19 Testing System in Saudi Arabia
5. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
6. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
7. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
9. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
10. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, John ... Mr. Kelley, a recognized leader and mentor in the Denver area business ...
(Date:4/28/2016)... 2016 The report "Cryocooler Market ... Service (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, ... to 2022", published by MarketsandMarkets, the global market is ... at a CAGR of 7.29% between 2016 and 2022. ... 94 Figures spread through 159 Pages and in-depth TOC ...
(Date:4/28/2016)... New York, NY (PRWEB) , ... April 28, ... ... plan, QuickSTAT has made significant investments in recruiting top industry experts, and expanding ... IT Platform, which provides industry-leading tools for clients to manage their clinical trial ...
(Date:4/27/2016)... ... , ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” ... of Committee since 1987. Since then, he has served in a number of key ... for both the program and exposition committees. In his professional career, Dr. Gardner is ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):